Therawis Diagnostics' licensing and development partner QIAGEN launches predictive therascreen PITX2 test in Europe to guide treatment in high-risk breast cancer.

February 7, 2018

Therawis Diagnostics and QIAGEN enter into a development and commercialization agreement on predictive biomarkers in oncology.

May 26, 2016